A bill now moving through the House would hand Medicare something it does not currently have: the legal authority to pay for a blood test that screens for Alzheimer's disease and related dementias in people who show no symptoms. H.R.6130, the Alzheimer's Screening and Prevention Act, would amend the Social Security Act to create a new Medicare benefit category for what the bill calls an "Alzheimer's disease and related dementias early detection screening test," covering blood or blood product tests furnished on or after January 1, 2028, according to the bill text posted on Congress.gov and mirrored in the government's GovInfo repository. Rep. Vern Buchanan, Republican of Florida, introduced the bill on November 19, 2025, with Rep. Paul Tonko, Democrat of New York, signed on as cosponsor. A Senate companion, S.3267, followed one day later, introduced by Sen. Susan Collins, Republican of Maine, with cosponsors from both parties.

Medicare covers a mammogram or a colonoscopy because Congress wrote that coverage into law, test by test, disease by disease. It has never done that for dementia. Current statute keeps Medicare from paying for a screening test, one given before any symptom or diagnosis, until lawmakers carve out that authority first. H.R.6130 would carve out that authority specifically for blood-based dementia tests, opening a door Congress has never opened for this disease. It leaves the Centers for Medicare and Medicaid Services' own evidence review in place to decide which tests qualify and under what conditions, a distinction the Alzheimer's Association has drawn for lawmakers directly. Passing the bill would clear no single test for payment on its own. The Food and Drug Administration still decides whether a given test works. CMS still decides, separately, whether Medicare pays for it.

The bill's momentum became visible this fall. On September 15, 2026, the House Energy and Commerce Committee's Health Subcommittee held a hearing covering several Medicare bills, and the record the committee posted afterward included letters urging support for H.R.6130. Ten days before that hearing, on August 25, 2026, the Alzheimer's Association, the Alzheimer's Impact Movement and the LEAD Coalition said more than 525 organizations, researchers and clinicians had signed a letter asking Congress to move the bill forward. That pressure has produced hearings and letters, not a vote. As of this week, H.R.6130 sits in committee, with no floor vote scheduled, and its Senate companion has gone no further than committee referral.